Skip to main content
Trial shows positive results for W.L. Gore's septal occluders

A 664-patient, 63-site trial presented at the European Stroke Organisation Conference showed use of W.L. Gore & Associates' Cardioform septal occluder or its earlier-generation Helex septal occluder plus antiplatelet drugs in patients with a patent foramen ovale and a history of stroke led to a 76.6% reduction in recurrent ischemic stroke compared with antiplatelet therapy alone. Results of the trial are expected to support the company's FDA application for a patent foramen ovale indication for the Cardioform device by year's end.

Full Story: